Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
MELLIN GW, 1962, NEW ENGL J MED, V267, P1184 MELLIN GW, 1962, NEW ENGL J MED, V267, P1238 LENZ W, 1961, DEUT MED WOCHENSCHR, V86, P2555 LENZ W, 1962, DEUT MED WOCHENSCHR, V87, P1232 KUNZ W, 1956, ARZNEIMITTEL-FORSCH, V6, P426 SHESKIN J, 1965, LEPROSY REV, V36, P183 WIEDEMANN HR, 1961, MED WELT, V37, P1863 BECKMANN R, 1962, ARZNEIMITTEL-FORSCH, V12, P1095 |
Nodes: 2685,
Authors: 6203,
Journals: 662,
Outer References: 16023,
Words: 3995
Collection span: 1956 - 2004
View: Overview. Sorted by first author.
Page 5: 1 2 3 4 5 6 7 8 9
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
---|---|---|---|---|---|
1201 | 3 | 8 | 770 1981 ZEITSCHRIFT FUR NATURFORSCHUNG C-A JOURNAL OF BIOSCIENCES 36(9-10):904-906 KOCHERBECKER U; KOCHER W; OCKENFELS H THALIDOMIDE-LIKE MALFORMATIONS CAUSED BY A TWEEN SURFACTANT IN MICE | 3 | 6 |
1202 | 4 | 10 | 785 1982 NATURWISSENSCHAFTEN 69(4):191-192 KOCHERBECKER U; KOCHER W; OCKENFELS H TERATOGENIC ACTIVITY OF A HYDROLYTIC THALIDOMIDE METABOLITE IN MICE | 3 | 4 |
1203 | 6 | 37 | 1080 1992 ZEITSCHRIFT FUR NATURFORSCHUNG C-A JOURNAL OF BIOSCIENCES 47(1-2):155-169 KOCHERBECKER U; KOCHER W; OCKENFELS H EMBRYOTOXIC INTERACTIONS BETWEEN A HYDROLYSIS PRODUCT OF THALIDOMIDE AND THE SURFACTANT TWEEN 20 IN MICE | 0 | 0 |
1204 | 9 | 21 | 590 1974 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 24(10):1616-1619 KOHLER F; KOCH H TERATOLOGY STUDY ON THALIDOMIDE-LIKE COMPOUNDS K-2004 AND K-2604 IN MOUSE AND RAT | 9 | 21 |
1205 | 7 | 13 | 523 1971 EXPERIENTIA 27(10):1149-& KOHLER F; MEISE W; OCKENFEL.H TERATOLOGICAL TESTING OF SOME THALIDOMIDE METABOLITES | 6 | 17 |
1206 | 2 | 5 | 521 1971 EXPERIENTIA 27(4):421-& KOHLER F; OCKENFEL.H COMPENSATION OF TERATOGENIC EFFECT OF A THALIDOMIDE METABOLITE BY L-GLUTAMIC ACID | 3 | 7 |
1207 | 0 | 0 | 119 1962 LANCET 1(7224):326-& KOHLER HG; FISHER AM; DUNN PM THALIDOMIDE AND CONGENITAL ABNORMALITIES | 7 | 17 |
1208 | 0 | 0 | 2304 2003 AMERICAN JOURNAL OF HUMAN GENETICS 73(5):197-197 Kohlhase J; Schubert L; Liebers M; Hennekam RCM; Rauch A; Becker K; Mohammed SN; Wright M; Hannibal MC; Newbury-Ecob R; Reardon W SALL4 mutations result in a range of clinically overlapping phenotypes, including Okihiro syndrome, Holt-Oram syndrome, Acro-Reno-Ocular syndrome and patients previously reported to represent Thalidomide Embryopathy. | 0 | 0 |
1209 | 1 | 27 | 2489 2003 JOURNAL OF MEDICAL GENETICS 40(7):473-478 Kohlhase J; Schubert L; Liebers M; Rauch A; Becker K; Mohammed SN; Newbury-Ecob R; Reardon W Mutations at the SALL4 locus on chromosome 20 result in a range of clinically overlapping phenotypes, including Okihiro syndrome, Holt-Oram syndrome, acro-renal-ocular syndrome, and patients previously reported to represent thalidomide embryopathy | 0 | 2 |
1210 | 6 | 15 | 2016 2002 ACTA DERMATO-VENEREOLOGICA 82(5):384-386 Kolde G; Schulze P; Sterry W Mixed response to thalidomide therapy in adults: Two cases of multisystem Langerhans' cell histiocytosis | 1 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1211 | 11 | 18 | 2446 2003 DERMATOLOGY 206(4):381-383 Kolivras A; De Maubeuge J; Andre J; Song M Thalidomide in refractory vulvar ulcerations associated with Crohn's disease | 1 | 1 |
1212 | 0 | 0 | 654 1977 OBSIDIAN-BLACK LITERATURE IN REVIEW 3(1):53-53 KOMUNYAKAA Y 'THALIDOMIDE' | 0 | 0 |
1213 | 7 | 10 | 299 1964 POULTRY SCIENCE 43(6):1420-& KONDRA PA; SELL JL; MCKIRDY JA EFFECT OF THALIDOMIDE ON REPRODUCTION IN HEN | 2 | 4 |
1214 | 5 | 19 | 457 1968 CANADIAN JOURNAL OF ANIMAL SCIENCE 48(3):285-& KONDRA PA; SELL JL; MCKIRDY JA EFFECT OF THALIDOMIDE ON EMBRYONIC AND POST-EMBRYONIC DEVELOPMENT OF CHICK | 0 | 0 |
1215 | 0 | 0 | 1479 1999 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 217:U88-U88 Konnecke WE; Smith AM; Khetani VD A two step synthesis of thalidomide. | 0 | 0 |
1216 | 83 | 113 | 1630 2000 BIODRUGS 13(4):255-265 Kontogiannis V; Powell RJ Use of thalidomide in dermatological indications | 0 | 0 |
1217 | 1 | 8 | 300 1964 PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE 116(2):512-& KORANSKY W; ULLBERG S AUTORADIOGRAPHIC INVESTIGATIONS OF 14C-LABELLED THALIDOMIDE + GLUTETHIMIDE IN PREGNANT MICE | 5 | 15 |
1218 | 0 | 0 | 1436 1998 GEBURTSHILFE UND FRAUENHEILKUNDE 58(3):M55-M58 Kosenow W Forty years ago: Thalidomide and its consequences | 0 | 0 |
1219 | 20 | 40 | 1603 1999 SURGERY 125(5):536-544 Kotoh T; Dhar DK; Masunaga R; Tabara H; Tachibana M; Kubota H; Kohno H; Nagasue N Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice | 12 | 27 |
1220 | 0 | 0 | 34 1961 BRITISH MEDICAL JOURNAL 2(526):1498-& KREMER M; FULLERTON PM NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 2 | 3 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1221 | 6 | 13 | 1063 1992 JOURNAL OF PHARMACEUTICAL SCIENCES 81(7):685-689 KRENN M; GAMCSIK MP; VOGELSANG GB; COLVIN OM; LEONG KW IMPROVEMENTS IN SOLUBILITY AND STABILITY OF THALIDOMIDE UPON COMPLEXATION WITH HYDROXYPROPYL-BETA-CYCLODEXTRIN | 9 | 16 |
1222 | 7 | 29 | 1196 1995 GENERAL PHARMACOLOGY 26(6):1243-1247 KROGER H; KLEWER M; GRATZ R; DIETRICH A; OCKENFELS H; MIESEL R EXACERBATION OF ACETAMINOPHEN HEPATOTOXICITY BY THALIDOMIDE AND PROTECTION BY NICOTINIC-ACID AMIDE | 1 | 2 |
1223 | 11 | 43 | 1269 1996 INFLAMMATION 20(2):203-215 Kroger H; Miesel R; Dietrich A; Ohde M; Rajnavolgyi E; Ockenfels H Synergistic effects of thalidomide and poly(ADP-ribose) polymerase inhibition on type II collagen-induced arthritis in mice | 1 | 12 |
1224 | 0 | 0 | 1639 2000 BLOOD 96(11):168A-168A Kropff MH; Innig G; Mitterer M; Straka C; Ostermann H; Koch OM; Berdel WE; Kienast J Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (Hyper-CDT) in primary refractory or relapsed multiple myeloma. | 0 | 7 |
1225 | 19 | 40 | 2418 2003 BRITISH JOURNAL OF HAEMATOLOGY 122(4):607-616 Kropff MH; Lang N; Bisping G; Domine N; Innig G; Hentrich M; Mitterer M; Sudhoff T; Fenk R; Straka C; Heinecke A; Koch OM; Ostermann H; Berdel WE; Kienast J Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma | 4 | 8 |
1226 | 0 | 0 | 2111 2002 BLOOD 100(11):402A-403A Kropff MH; Lang N; Bisping G; Domine N; Schneider P; Suedhoff T; Innig G; Straka C; Ostermann H; Berdel WE; Kienast J Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in advanced multiple myeloma: Final results of a phase II trial. | 0 | 1 |
1227 | 28 | 123 | 1912 2001 CURRENT OPINION IN ONCOLOGY 13(5):374-381 Krown SE Management of Kaposi sarcoma: the role of interferon and thalidomide | 2 | 17 |
1228 | 2 | 53 | 524 1971 FORTSCHRITTE DER NEUROLOGIE UND PSYCHIATRIE UND IHRER GRENZGEBIETE 39(1):15-& KRUCKE W; HARTROTT HH; SCHRODER JM; THOMAS E; GIBBELS E; SCHEID W LIGHT AND ELECTRON MICROSCOPIC STUDIES ON LATE STAGE OF THALIDOMIDE POLYNEUROPATHY | 13 | 18 |
1229 | 13 | 27 | 1437 1998 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 236(6):461-466 Kruse FE; Joussen AM; Rohrschneider K; Becker MD; Volcker HE Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor | 39 | 57 |
1230 | 3 | 3 | 1986 2001 NEW ENGLAND JOURNAL OF MEDICINE 345(16):1214-1215 Kudva GC; Collins BT; Dunphy FR Thalidomide for malignant melanoma. | 1 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1231 | 0 | 0 | 15 1961 BRITISH MEDICAL JOURNAL 1(522):291-& KUENSSBERG EV; STANTON JB; SIMPSON JA IS THALIDOMIDE TO BLAME | 10 | 13 |
1232 | 54 | 68 | 1944 2001 HAUTARZT 52(8):726-733 Kuhn A; Hefter H; Ruzicka T; Lehmann P Rediscovery of thalidomide. Successful treatment of discoid lupus erythematosus | 0 | 0 |
1233 | 0 | 0 | 8 1960 FEDERATION PROCEEDINGS 19(1):264-264 KUHN WL; VANMAANEN EF EFFECTS OF THALIDOMIDE ON CENTRAL NERVOUS SYSTEM DRUGS | 2 | 4 |
1234 | 4 | 24 | 43 1961 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 134(1):60-& KUHN WL; VANMAANEN EF CENTRAL NERVOUS SYSTEM EFFECTS OF THALIDOMIDE | 8 | 85 |
1235 | 0 | 0 | 1315 1997 BLOOD 90(10):1673-1673 Kulkarni S; Powles R; Mehta J; Horton C; Treleaven J; Meller S; Atra A; Pinkerton CR; Singhal S Thalidomide is very effective for chronic GVHD but has no activity in acute GVHD. | 0 | 0 |
1236 | 0 | 0 | 1415 1998 BLOOD 92(10):344B-344B Kulkarni S; Powles R; Mehta J; Horton C; Treleaven J; Meller S; Atra A; Pinkerton CR; Singhal S Thalidomide in GVHD - S anti-GVHD effect separable from the antiangiogenesis? | 0 | 4 |
1237 | 0 | 0 | 1248 1996 BLOOD 88(10):2424-2424 Kulkarni S; Powles R; Mehta J; Horton C; Treleaven J; Middleton G; Eisen T; Singhal S Thalidomide for acute or chronic graft-versus-host disease. | 0 | 0 |
1238 | 13 | 35 | 2402 2003 BONE MARROW TRANSPLANTATION 32(2):165-170 Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease | 0 | 1 |
1239 | 0 | 1 | 2637 2004 JOURNAL OF CLINICAL ONCOLOGY 22(14):2973-2973 Kumar Thalidomide: Current role in the treatment of non-plasma cell malignancies (vol 22, pg 2477, 20040 | 0 | 0 |
1240 | 23 | 39 | 2532 2003 MAYO CLINIC PROCEEDINGS 78(1):34-39 Kumar S; Gertz MA; Dispenzieri A; Lacy MQ; Geyer SM; Iturria NL; Fonseca R; Hayman SR; Lust JA; Kyle RA; Greipp PR; Witzig TE; Rajkumar SV Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma | 9 | 20 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1241 | 11 | 40 | 2656 2004 LEUKEMIA 18(3):624-627 Kumar S; Witzig TE; Dispenzieri A; Lacy MQ; Wellik LE; Fonseca R; Lust JA; Gertz MA; Kyle RA; Greipp PR; Rajkumar SV Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma | 1 | 1 |
1242 | 41 | 67 | 2215 2002 JOURNAL OF CELLULAR AND MOLECULAR MEDICINE 6(2):160-174 Kumar S; Witzig TE; Rajkumar SV Thalidomide as an anti-cancer agent | 6 | 10 |
1243 | 0 | 0 | 2367 2003 BLOOD 102(11):387B-387B Kumar S; Witzig TE; Wellik L; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Kyle RA; Gertz MA; Greipp PR; Rajkumar SV Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. | 0 | 0 |
1244 | 0 | 13 | 1 1956 ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH 6(8):426-430 KUNZ W; KELLER H; MUCKTER H N-PHTHALYL-GLUTAMINIC IMIDE | 40 | 76 |
1245 | 0 | 1 | 1977 2001 LIBRARY JOURNAL 126(7):126-126 Kupferberg N Dark remedy: The impact of thalidomide and its revival as a vital medicine. | 0 | 0 |
1246 | 2 | 2 | 879 1985 BRITISH JOURNAL OF DERMATOLOGY 112(5):632-632 KURKCUOGLU N; ATAKAN N; EKSIOGLU M THALIDOMIDE IN THE TREATMENT OF RECURRENT NECROTIC MUCOCUTANEOUS APHTHAE | 13 | 16 |
1247 | 1 | 1 | 2272 2002 ONCOLOGY-NEW YORK 16(1):21-22 Kurstin R Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease | 1 | 1 |
1248 | 7 | 21 | 2007 2001 SEMINARS IN ONCOLOGY 28(6):583-587 Kyle RA; Rajkumar SV Therapeutic application of thalidomide in multiple myeloma | 5 | 9 |
1249 | 16 | 22 | 1727 2000 INTERNATIONAL JOURNAL OF DERMATOLOGY 39(3):218-222 Kyriakis KP; Kontochristopoulos GJ; Panteleos DN Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus | 10 | 17 |
1250 | 0 | 0 | 2366 2003 BLOOD 102(11):386B-386B Kyriakou CA; D'Sa SP; Flory A; Hanslip J; Peggs KS; Yong KL Cyclophosphamide, dexamethasone and thalidomide (CDT) is a well tolerated and effective regimen in advanced relapsed/refractory myeloma. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1251 | 2 | 4 | 1828 2001 BLOOD 97(8):2527-2528 Kyrtsonis MC; Kokoris SI; Kontopidou FN; Siakantaris MP; Kittas C; Pangalis GA Development of a myeloproliferative disorder in a patient with monoclonal gammopathy of undetermined significance secreting immunoglobulin of the M class and treated with thalidomide and anti-CD20 monoclonal antibody | 0 | 1 |
1252 | 8 | 33 | 1693 2000 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 119(1):123-129 La Maestra L; Zaninoni A; Marriott JB; Lazzarin A; Dalgleish AG; Barcellini W The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro | 10 | 18 |
1253 | 0 | 0 | 2375 2003 BLOOD 102(11):453A-453A Lacy MQ; Dispenzieri A; Gertz MA; Wilzig TE; Greipp PR; Fonseca R; Lust JA; Kumar S; Zeldenrust S; Kyle RA; Snow D; Hayman SR; Sidor CF; Treston AM; Zeldis JB; Rajkumar SV ENMD-0995 (S 3-APG), a novel thalidomide analogue, has promising clinical activity for patients with relapsed refractory multiple myeloma. Preliminary results of a phase I clinical trial. | 0 | 1 |
1254 | 0 | 1 | 591 1974 BRITISH JOURNAL OF PSYCHIATRY 124(MAY):498-499 LADER M THALIDOMIDE AND POWER OF DRUG COMPANIES - SJOSTROM,H AND NILSSON,R | 0 | 0 |
1255 | 91 | 116 | 1617 2000 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 127(6-7):603-613 Laffitte E; Revuz J Thalidomide | 7 | 8 |
1256 | 19 | 41 | 929 1986 MUSCLE & NERVE 9(9):837-844 LAGUENY A; ROMMEL A; VIGNOLLY B; TAIEB A; VENDEAUDBUSQUET M; DOUTRE MS; JULIEN J THALIDOMIDE NEUROPATHY - AN ELECTROPHYSIOLOGIC STUDY | 21 | 28 |
1257 | 5 | 24 | 443 1967 SPERIMENTALE 117(6):465-& LAI P; PALMIERI G TERATOGENIC EFFECTS OF THALIDOMIDE IN CHICKEN AND RABBIT | 0 | 0 |
1258 | 0 | 1 | 480 1969 BOLLETTINO DELLA SOCIETA ITALIANA DI BIOLOGIA SPERIMENTALE 45(20A):62-& LAI P; PALMIERI G INFLUENCE OF THALIDOMIDE ON REPRODUCTIVE CAPACITY OF CHICKENS | 0 | 0 |
1259 | 8 | 11 | 1475 1998 REVUE DE MEDECINE INTERNE 19(3):196-198 Lair G; Marie I; Cailleux N; Blot E; Boullie MC; Courville P; Lauret P; Levesque H; Courtois H Langerhans cell histiocytosis in adult patients: cutaneous and mucous localizations improving with thalidomide | 9 | 13 |
1260 | 0 | 0 | 2167 2002 CLINICAL PHARMACOLOGY & THERAPEUTICS 71(2):P83-P83 Lakhani N; Gordon S; Figg W; Dionne R Absorption and adverse effects of topical thalidomide. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1261 | 0 | 0 | 679 1978 SCIENCES ET TECHNIQUES DE L ANIMAL DE LABORATOIRE 3(4):233-242 LANDSMANN F; COLLIN A; LAINE H; MAZUE G EMBRYOPATHIES INDUCED BY THALIDOMIDE IN MACACA-IRUS | 0 | 2 |
1262 | 0 | 0 | 1274 1996 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 37(3):3032-3032 Lansing MB; Dixit S; Glaser BM The effect of systemic thalidomide and amiloride on neovascularization in the rabbit corneal micropocket essay | 0 | 0 |
1263 | 0 | 0 | 1576 1999 LANCET 354(9182):925-925 Larkin M Low-dose thalidomide seems to be effective in multiple myeloma | 9 | 14 |
1264 | 0 | 0 | 1577 1999 LANCET 354(9191):1705-1705 Larkin M Thalidomide continues to look promising as an anticancer agent | 1 | 1 |
1265 | 15 | 28 | 184 1963 ACTA PHARMACOLOGICA ET TOXICOLOGICA 20(3):186-& LARSEN V TERATOGENIC EFFECTS OF THALIDOMIDE, IMIPRAMINE HCL AND IMIPRAMINE-N-OXIDE HCL ON WHITE DANISH RABBITS | 5 | 20 |
1266 | 0 | 0 | 186 1963 ACTA PHYSIOLOGICA SCANDINAVICA 59:87-& LARSEN V TERATOGENIC EFFECTS OF THALIDOMIDE, IMIPRAMINE HCL AND IMIPRAMINE N-OXIDE HCL ON WHITE DANISH RABBITS | 0 | 0 |
1267 | 1 | 11 | 360 1966 ACTA PHARMACOLOGICA ET TOXICOLOGICA 24(4):443-& LARSEN V; BREDAHL E EMBRYOTOXIC EFFECT ON RABBITS OF MONOPHENYLBUTAZONE (MONAZAN) COMPARED WITH PHENYLBUTAZONE AND THALIDOMIDE | 1 | 9 |
1268 | 7 | 14 | 1017 1990 JOURNAL OF INTERNAL MEDICINE 228(4):405-407 LARSSON H TREATMENT OF SEVERE COLITIS IN BEHCETS-SYNDROME WITH THALIDOMIDE (CG-217) | 19 | 34 |
1269 | 15 | 23 | 1535 1999 DRUG SAFETY 21(3):161-169 Lary JM; Daniel KL; Erickson JD; Roberts HE; Moore CA The return of thalidomide - Can birth defects be prevented? | 5 | 10 |
1270 | 2 | 7 | 528 1971 NATURE 232(5313):634-& LASH JW; SAXEN L EFFECT OF THALIDOMIDE ON HUMAN EMBRYONIC TISSUES | 7 | 18 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1271 | 5 | 24 | 550 1972 DEVELOPMENTAL BIOLOGY 28(1):61-& LASH JW; SAXEN L HUMAN TERATOGENESIS - IN-VITRO STUDIES ON THALIDOMIDE-INHIBITED CHONDROGENESIS | 9 | 26 |
1272 | 1 | 10 | 627 1976 OPHTHALMIC RESEARCH 8(2):146-151 LASZCZYK WA; NACIAZEKWIENIAWSKA A; WITOWSKAVEIT M CHANGES IN VISUAL-SYSTEM OF RABBIT FETUSES AFTER THALIDOMIDE ADMINISTRATION | 0 | 0 |
1273 | 0 | 0 | 2387 2003 BLOOD 102(11):687A-687A Latif T; Elson P; Karam MA; Reed J; Tahir K; Srkalovic G; Hussein MA Incidence of renal impairment (RI) in multiple myeloma (MM) patients receiving combination chemotherapy and thalidomide (Thal) with bisphosphonate therapy. | 0 | 0 |
1274 | 1 | 5 | 814 1983 CLINICAL AND EXPERIMENTAL DERMATOLOGY 8(2):208-209 LAURET P THALIDOMIDE AND THE MANAGEMENT OF LUPUS-ERYTHEMATOSUS | 0 | 1 |
1275 | 0 | 0 | 205 1963 CANADIAN MEDICAL ASSOCIATION JOURNAL 88(19):962-& LAZURE D HABILITATION OF PATIENTS WITH CONGENITAL MALFORMATIONS ASSOCIATED WITH THALIDOMIDE - PSYCHIATRIC AND PSYCHOLOGICAL ASPECTS | 1 | 1 |
1276 | 0 | 0 | 2351 2003 BLOOD 102(11):330B-330B Leb LV; Becker P; Brettler D; Church AA; Khanani SA; Rooney JJ; Seidler CW; Yang J; Woda B The potentiating effect of low dose thalidomide given in combination with epoetin alfa in patients with myelodysplastic syndrome (MDS) having low International Prognostic Scoring Systems (IPSS). | 0 | 0 |
1277 | 0 | 0 | 2117 2002 BLOOD 100(11):671A-671A LeBlanc R; Hideshima T; Hayashi T; Catley LP; Burger R; Shringarpure R; Cheema P; Richardson P; Anderson KC; Munshi NC Thalidomide analogue IMiD3 provides T cell co-stimulation through B7-CD28 pathway. | 0 | 0 |
1278 | 11 | 34 | 84 1962 BRITISH MEDICAL JOURNAL 2(5296):14-& LECK IM; MILLAR ELM INCIDENCE OF MALFORMATIONS SINCE INTRODUCTION OF THALIDOMIDE | 25 | 64 |
1279 | 3 | 5 | 81 1962 BRITISH MEDICAL JOURNAL (5317):1447-& LECUTIER MA PHOCOMELIA AND INTERNAL DEFECTS DUE TO THALIDOMIDE | 0 | 0 |
1280 | 7 | 25 | 2480 2003 JOURNAL OF CLINICAL ONCOLOGY 21(14):2732-2739 Lee CK; Barlogie B; Munshi N; Zangari M; Fassas A; Jacobson J; van Rhee F; Cottler-Fox M; Muwalla F; Tricot G DTPACE: An effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma | 2 | 8 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1281 | 4 | 4 | 2055 2002 BLOOD 99(11):4248-4248 Lee FC Second response to lower-dose thalidomide in a patient with multiple myeloma | 2 | 2 |
1282 | 4 | 37 | 2301 2003 AMERICAN JOURNAL OF HEMATOLOGY 73(1):48-53 Lee FC; Merchant SH Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide | 1 | 2 |
1283 | 11 | 18 | 1455 1998 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 39(5):835-838 Lee JB; Koblenzer PS Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: A case report | 14 | 29 |
1284 | 6 | 6 | 1819 2001 ARTHRITIS AND RHEUMATISM 44(10):2456-2457 Lee L; Lawford R; McNeil HP The efficacy of thalidomide in severe refractory seronegative spondylarthropathy: comment on the letter by Breban et al | 2 | 5 |
1285 | 0 | 0 | 1243 1996 ARTHRITIS AND RHEUMATISM 39(9):1524-1524 Lee S; Klausner J; Oliver S; Kaplan G; McCullagh E Treatment of rheumatoid arthritis (RA) with thalidomide | 1 | 1 |
1286 | 0 | 0 | 1816 2001 ARTHRITIS AND RHEUMATISM 44(9):S272-S272 Lehman TJ; Striegel KH; Onel KB Thalidomide therapy for corticosteroid dependent systemic onset juvenile rheumatoid arthritis | 0 | 1 |
1287 | 7 | 20 | 2240 2002 JOURNAL OF PEDIATRICS 140(1):125-127 Lehman TJA; Striegel KH; Onel KB Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis | 4 | 7 |
1288 | 11 | 17 | 536 1971 TOXICOLOGY AND APPLIED PHARMACOLOGY 18(1):208-& LEHMANN H; NIGGESCH.A TERATOLOGIC EFFECTS OF THALIDOMIDE IN HIMALAYAN RABBITS | 2 | 11 |
1289 | 1 | 10 | 897 1985 LANCET 1(8423):288-289 LEHNER T; SULLIVAN FM THALIDOMIDE, OROGENITAL ULCERS, AND THE RISK OF TERATOGENESIS | 1 | 3 |
1290 | 3 | 5 | 2276 2002 ONCOLOGY-NEW YORK 16(9):1146-+ Leibowitz R; Tucker SJ PSA response to thalidomide in patients with advanced prostate cancer | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1291 | 0 | 0 | 1653 2000 BLOOD 96(11):290B-290B Leleu X; Cornillon J; Magro L; Guillerm G; Dalle JH; Fenaux P; Jouet JP; Bauters F; Facon T; Yakoub-Agha I Is thalidomide 50 mg/d as a minimal first dose effective in advanced myeloma? | 0 | 2 |
1292 | 1 | 3 | 2059 2002 BLOOD 100(4):1519-1520 Leleu X; Magro L; Fawaz A; Bauters F; Facon T; Yakoub-Agha I Efficacy of a low dose of thalidomide in advanced multiple myeloma | 7 | 7 |
1293 | 44 | 51 | 1733 2000 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 6(1):19-26 Lenardo TM; Calabrese LH The role of thalidomide in the treatment of rheumatic disease | 4 | 4 |
1294 | 0 | 0 | 2392 2003 BLOOD 102(11):829A-830A Lentzsch S; Koh KR; Stirling D; Zenke M; Dorken B Immunomodulatory derivative of thalidomide (IMiD CC-4047) determine the lineage commitment of hematopoietic progenitors by down regulation of GATA-1 and modulation of cytokine secretion. | 0 | 0 |
1295 | 8 | 17 | 2515 2003 LEUKEMIA 17(1):41-44 Lentzsch S; LeBlanc R; Podar K; Davies F; Lin B; Hideshima T; Catley L; Stirling DI; Anderson KC Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo | 7 | 16 |
1296 | 0 | 0 | 1671 2000 BLOOD 96(11):579A-+ Lentzsch S; Podar K; Davies FE; Hideshima T; Tai YT; Chauhan D; Lin BK; Treon SP; Gupta D; Mitsiades C; Mitsiades N; Hayashi T; Muller GW; Stirling DI; Anderson KC Immunomodulatory derivatives (IMiDs) of thalidomide (Thal) inhibit the proliferation of multiple myeloma (MM) cell lines and block VEGF-induced activation of the MAPK-pathway. | 0 | 2 |
1297 | 0 | 0 | 41 1961 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 86(52):2555-& LENZ W KINDLICHE MISSBILDUNGEN NACH MEDIKAMENT-EINNAHME WAHREND DER GRAVIDITAT | 60 | 144 |
1298 | 0 | 0 | 110 1962 LANCET 1(7219):45-& LENZ W THALIDOMIDE AND CONGENITAL ABNORMALITIES | 122 | 254 |
1299 | 0 | 0 | 115 1962 LANCET 1(7223):271-& LENZ W THALIDOMIDE AND CONGENITAL ABNORMALITIES - REPLY | 22 | 47 |
1300 | 1 | 8 | 374 1966 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 91(24):1132-& LENZ W CAN THALIDOMIDE SUPPRESS IMMUNOLOGICAL REACTIONS | 2 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1301 | 4 | 8 | 430 1967 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 92(47):2186-& LENZ W SENSITIVE PHASE OF THALIDOMIDE EMBRYOPATHIES IN MONKEYS AND MEN | 0 | 1 |
1302 | 1 | 3 | 439 1967 LANCET 2(7515):562-& LENZ W PERTHES-LIKE CHANGES IN THALIDOMIDE CHILDREN | 0 | 0 |
1303 | 0 | 0 | 943 1987 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 112(9):365-365 LENZ W THALIDOMIDE-CAUSED BIRTH-DEFECTS | 0 | 0 |
1304 | 2 | 8 | 980 1988 TERATOLOGY 38(3):203-215 LENZ W A SHORT HISTORY OF THALIDOMIDE EMBRYOPATHY | 38 | 69 |
1305 | 0 | 0 | 1075 1992 TERATOLOGY 46(5):417-418 LENZ W A PERSONAL PERSPECTIVE ON THE THALIDOMIDE TRAGEDY | 2 | 5 |
1306 | 6 | 14 | 53 1962 ARCHIVES OF ENVIRONMENTAL HEALTH 5(2):100-& LENZ W; KNAPP K THALIDOMIDE EMBRYOPATHY | 10 | 62 |
1307 | 5 | 15 | 97 1962 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 87(24):1232-& LENZ W; KNAPP K DIE THALIDOMID-EMBRYOPATHIE | 48 | 144 |
1308 | 15 | 23 | 2643 2004 JOURNAL OF MEDICINAL CHEMISTRY 47(9):2219-2227 Lepper ER; Ng SSW; Gutschow M; Weiss M; Hauschildt S; Hecker TK; Luzzio FA; Eger K; Figg WD Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors | 0 | 0 |
1309 | 0 | 0 | 1346 1997 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 38(4):1240-1240 Lesk MR; Ponomarenko S; Filion B; Burnier M Effect of oral thalidomide on prolongation of rabbit sclerostomy function. | 0 | 0 |
1310 | 0 | 0 | 615 1975 LANCET 1(7913):985-985 LESSER E POSTSCRIPT TO THALIDOMIDE | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1311 | 0 | 0 | 825 1983 KEMISK TIDSKRIFT 95(12):74-74 LEVERBECK K SECRET TEST REVEALS THE MUTAGENIC EFFECT OF THALIDOMIDE | 0 | 0 |
1312 | 2 | 12 | 1256 1996 CLINICAL INFECTIOUS DISEASES 23(3):504-505 Levine AM Editorial response - Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide | 1 | 1 |
1313 | 0 | 1 | 696 1979 HASTINGS CENTER REPORT 9(3):43-44 LEVINE C SUFFER THE CHILDREN - STORY OF THALIDOMIDE - SUNDAY-TIMES-OF-LONDON - INSIGHT-TEAM | 0 | 0 |
1314 | 2 | 2 | 573 1973 LANCET 2(7824):324-325 LEVY L; FASAL P; LEVAN NE; FREEDMAN RI TREATMENT OF ERYTHEMA-NODOSUM LEPROSUM WITH THALIDOMIDE | 8 | 10 |
1315 | 1 | 2 | 1574 1999 LANCET 353(9149):324-324 Levy R Thalidomide in toxic epidermal necrolysis | 1 | 2 |
1316 | 2 | 13 | 1271 1996 INTERNATIONAL JOURNAL OF STD & AIDS 7(7):518-520 Lewis DA; Amerasinghe CN; Murphy SM Successful treatment of Behcet's syndrome in an African female patient with thalidomide | 2 | 3 |
1317 | 1 | 1 | 453 1968 BRITISH JOURNAL OF HAEMATOLOGY 15(3):322-& LEWIS HBM; ALBERTRE.F; WALKER W COLD HAEMAGGLUTINATION DISEASE TREATED BY THALIDOMIDE | 0 | 5 |
1318 | 5 | 7 | 2003 2001 SCIENTIST 15(2):1-+ Lewis R The return of thalidomide | 0 | 1 |
1319 | 0 | 0 | 1587 1999 NEUROLOGY 52(6):A424-A425 Li HW; Zhu LX; Karpati G; Nalbantoglu J Effect of thalidomide on growth of experimental intracerebral gliomas | 0 | 0 |
1320 | 3 | 29 | 2495 2003 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 31(1):19-27 Li JY; Jaworsky MS; Stirling DI The determination of a potential impurity in Thalidomide drug substance and product by HPLC with indirect UV detection | 0 | 1 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1321 | 6 | 17 | 2320 2003 ANTICANCER RESEARCH 23(3B):2481-2487 Li XP; Liu XY; Wang J; Wang ZL; Jiang W; Reed E; Zhang Y; Liu YL; Li QQ Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells | 0 | 0 |
1322 | 7 | 20 | 2469 2003 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 11(6):785-790 Li XP; Liu XY; Wang J; Wang ZL; Jiang W; Reed E; Zhang Y; Liu YL; Li QQ Effects of thalidomide on the expression of angiogenesis growth factors in human A(549) lung adenocarcinoma cells | 0 | 0 |
1323 | 20 | 72 | 539 1971 ZEITSCHRIFT FUR NEUROLOGIE 200(3):219-& LIEBALDT GP; BROSER F WHAT IS RELEVANCE VARIOUS PREVIOUS DAMAGES OF PERIPHERAL NERVOUS SYSTEM TO A THALIDOMIDE POLYNEUROPATHY - CLINICO-NEUROPATHOLOGIC DIFFERENTIAL DIAGNOSIS OF DIFFERENT TYPES OF POLYNEURITIS AND POLYNEUROPATHY | 0 | 0 |
1324 | 8 | 38 | 1895 2001 BRITISH JOURNAL OF PHARMACOLOGY 133(8):1414-1423 Lienenluke B; Stojanovic T; Fiebig T; Fayyazi A; Germann T; Hecker M Thalidomide impairment of trinitrobenzene sulphonic acid-induced colitis in the rat-role of endothelial cell-leukocyte interaction | 3 | 4 |
1325 | 0 | 1 | 595 1974 INTERNATIONAL JOURNAL OF HEALTH SERVICES 4(1):197-199 LIETMAN PS THALIDOMIDE AND POWER OF DRUG COMPANIES - SJOSTROM,H AND NILSSON,R | 0 | 0 |
1326 | 1 | 3 | 57 1962 BRITISH MEDICAL JOURNAL (5276):477-& LILLICRAP DA MYXOEDEMA AFTER THALIDOMIDE (DISTAVAL) | 0 | 0 |
1327 | 0 | 0 | 1413 1998 BLOOD 92(10):279B-279B Lim SH; Maclean R Thalidomide in IgA multiple myeloma. | 0 | 0 |
1328 | 4 | 4 | 970 1988 LANCET 1(8577):117-117 LIM SH; MCWHANNELL A; VORA AJ; BOUGHTON BJ SUCCESSFUL TREATMENT WITH THALIDOMIDE OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER BONE-MARROW TRANSPLANTATION | 32 | 35 |
1329 | 4 | 33 | 2050 2002 BIOORGANIC & MEDICINAL CHEMISTRY 10(9):3067-3073 Lima LM; Castro P; Machado AL; Fraga CAM; Lugnier C; de Moraes VLG; Barreiro EJ Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues | 2 | 6 |
1330 | 26 | 48 | 1999 2001 QUIMICA NOVA 24(5):683-688 Lima LM; Fraga CAM; Barreiro EJ The rebirth of a drug: Thalidomide | 0 | 1 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1331 | 7 | 34 | 2646 2004 JOURNAL OF PERIODONTOLOGY 75(1):162-168 Lima V; Vidal FDP; Rocha FAC; Brito GAC; Ribeiro RA Effects of tumor necrosis factor-alpha inhibitors pentoxifylline and thalidomide on alveolar bone loss in short-term experimental periodontal disease in rats | 0 | 0 |
1332 | 0 | 0 | 2086 2002 BLOOD 100(11):377B-377B Lincz LF; Enno A Thalidomide induced alterations in multiple myeloma cell surface receptor expression do not affect adhesion to bone marrow stroma or correlate with VEGF secretion in vitro. | 0 | 0 |
1333 | 3 | 8 | 242 1963 LANCET 2(730):405-& LINDAHLKIESSLIN.K; BOOK JA EFFECTS OF THALIDOMIDE ON HUMAN LEUCOCYTE CULTURES | 16 | 23 |
1334 | 0 | 0 | 474 1969 AMERICAN JOURNAL OF PHYSICAL ANTHROPOLOGY 31(2):267-& LINDBURG DG BEHAVIOR OF MONKEYS WITH THALIDOMIDE-INDUCED MALFORMATIONS | 0 | 0 |
1335 | 1 | 4 | 488 1969 PSYCHONOMIC SCIENCE 15(1):55-& LINDBURG DG BEHAVIOR OF INFANT RHESUS MONKEYS WITH THALIDOMIDE-INDUCED MALFORMATIONS - A PILOT STUDY | 0 | 6 |
1336 | 0 | 0 | 1651 2000 BLOOD 96(11):290B-290B Linder O; Tidefelt U Thalidomide combined with dexamethasone and pamidronate to patients with advanced myeloma, better than thalidomide alone? | 0 | 0 |
1337 | 0 | 0 | 1485 1999 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 159(3):A271-A271 Lindsay L; Oliver S; Freeman S; Regis J; Krauss A; Kaplan G The role of thalidomide and steroid in modulating the expression of TNF-alpha (TNA-a) and IL-6 in the hyperoxic newborn rat lung. | 0 | 0 |
1338 | 3 | 20 | 1725 2000 INFLAMMATION 24(4):347-356 Lindsay L; Oliver SJ; Freeman SL; Josien R; Krauss A; Kaplan G Modulation of hyperoxia-induced TNF-alpha expression in the newborn rat lung by thalidomide and dexamethasone | 1 | 5 |
1339 | 0 | 0 | 2252 2002 LANCET ONCOLOGY 3(12):711-711 Lindsey H Thalidomide plus dexamethasone for newly diagnosed myeloma | 0 | 0 |
1340 | 8 | 14 | 92 1962 CANADIAN MEDICAL ASSOCIATION JOURNAL 87(24):1259-& LING GM; DOLMAN CL; BOYD JR DRUG-INDUCED (THALIDOMIDE) MALFORMATIONS | 6 | 7 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1341 | 0 | 0 | 749 1981 ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY 52(3):S7-S7 LIPINSKI CG; WEISSER J PATHOLOGICAL EEG FINDINGS IN ADOLESCENTS WITH SEVERE SEQUELAE AFTER THALIDOMIDE EMBRYOPATHY | 0 | 0 |
1342 | 2 | 9 | 1074 1992 TERATOLOGY 46(5):411-413 LIPSON AH THALIDOMIDE RETROSPECTIVE - WHAT DID THE CLINICAL TERATOLOGIST LEARN | 0 | 3 |
1343 | 0 | 0 | 1645 2000 BLOOD 96(11):261B-261B Lisak LA; Little L; Dean L; Ekbal M; duRandt M; Hussain M; Kaistha V; Raza A Delayed responses to thalidomide in patients with myelodysplastic syndromes. | 0 | 0 |
1344 | 0 | 0 | 2065 2002 BLOOD 100(11):96A-96A List AF; Kurtin SE; Glinsmann-Gibson BJ; Bellamy WT; Buresh AJ; Waddleton D; Knight R High erythropoietic remitting activity of the immunomodulatory thalidomide analog, CC5013, in patients with myelodysplastic syndrome (MDS). | 0 | 3 |
1345 | 0 | 0 | 2068 2002 BLOOD 100(11):139A-139A List AF; Tate W; Glinsmann-Gibson BJ; Baker A The immunomodulatory thalidomide analog, CC5013, inhibits trophic response to VEGF in AML cells by abolishing cytokine-induced PI3-kinase/Akt activation. | 0 | 1 |
1346 | 13 | 67 | 1740 2000 JOURNAL OF CLINICAL ONCOLOGY 18(13):2593-2602 Little RF; Wyvill KM; Pluda JM; Welles L; Marshall V; Figg WD; Newcomb FM; Tosato G; Feigal E; Steinberg SM; Whitby D; Goedert JJ; Yarchoan R Activity of thalidomide in AIDS-related Kaposis's sarcoma | 44 | 82 |
1347 | 10 | 22 | 2242 2002 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 29(4):761-766 Liu T; Li MX; Li QY Electrochemical behavior of thalidomide | 0 | 0 |
1348 | 1 | 2 | 353 1965 PROCEEDINGS OF THE ROYAL SOCIETY OF MEDICINE-LONDON 58(7):493-& LIVINGST.G CONGENITAL EAR ABNORMALITIES DUE TO THALIDOMIDE | 0 | 30 |
1349 | 0 | 2 | 1027 1990 PRESSE MEDICALE 19(15):722-722 LIVROZET JM; FRANC C; GRANIER JL; BRETON P; TOURAINE JL THALIDOMIDE TREATMENT OF CHOICE OF APHTHAE IN HIV-INFECTION - REPLY | 0 | 0 |
1350 | 9 | 54 | 514 1971 ARCHIVES INTERNATIONALES DE PHARMACODYNAMIE ET DE THERAPIE 194(1):39-& LOCKER D; SUPERSTI.E; SULMAN FG MECHANISM OF PUSH AND PULL PRINCIPLE .8. ENDOCRINE EFFECTS OF THALIDOMIDE AND ITS ANALOGUES | 4 | 4 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1351 | 6 | 28 | 2513 2003 LEPROSY REVIEW 74(3):290-294 Lockwood D; Bryceson A The return of thalidomide: new uses and renewed concerns - reply | 0 | 2 |
1352 | 8 | 15 | 1748 2000 JOURNAL OF INFECTIOUS DISEASES 182(3):983-987 Lokensgard JR; Hu SX; van Fenema EM; Sheng WS; Peterson PK Effect of thalidomide on chemokine production by human microglia | 8 | 11 |
1353 | 0 | 0 | 19 1961 BRITISH MEDICAL JOURNAL 2(525):660-& LONGSTAFF JHL PURPURA ASSOCIATED WITH THALIDOMIDE | 0 | 0 |
1354 | 4 | 5 | 1089 1993 BONE MARROW TRANSPLANTATION 11(3):251-252 LOPEZ J; ULIBARRENA C; GARCIALARANA J; ODRIOZOLA J; DEOTEYZA JP; SASTRE JL; NAVARRO JL THALIDOMIDE AS THERAPY FOR INTESTINAL CHRONIC GVHD | 6 | 9 |
1355 | 8 | 34 | 1264 1996 HEPATOLOGY 23(6):1616-1621 LopezTalavera JC; Cadelina G; Olchowski J; Merrill W; Groszmann RJ Thalidomide inhibits tumor necrosis factor alpha decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats | 7 | 52 |
1356 | 6 | 15 | 2477 2003 JOURNAL OF CLINICAL ONCOLOGY 21(11):2211-2214 Loprinzi C; Rajkumar SV Why not start with thalidomide? | 0 | 1 |
1357 | 0 | 0 | 926 1986 LEPROSY REVIEW 57(1):76-77 LORETTI A; BARCHI E SUPPLIES OF THALIDOMIDE FOR USE IN LEPROSY | 1 | 1 |
1358 | 3 | 4 | 345 1965 NATURE 205(4971):621-& LORKIEWI.Z; DUDEK M; ZIEMIECK.J STIMULATION OF TRANSFORMATION BY THALIDOMIDE | 0 | 2 |
1359 | 1 | 5 | 1259 1996 ENDOSCOPY 28(5):471-472 Louvel D; Musso S; Metivier S; Croizet O; Rouquet RM; Massip P; Escourrou J; Frexinos J Idiopathic esophageal ulceration associated with human immunodeficiency virus infection: Efficacy of thalidomide treatment | 0 | 1 |
1360 | 1 | 6 | 1053 1992 ANNALES DE MEDECINE INTERNE 143(7):479-480 LOUZIR B; OTHMANI S; GRITLI N; BEJI M; ZIDI B; MSADDEK F; BOUSSEMA E; BAHRI M ACUTE MYELOID-LEUKEMIA IN A BEHCETS-DISEASE PATIENT UNDER LONG-TERM THALIDOMIDE TREATMENT | 0 | 3 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1361 | 7 | 21 | 805 1983 BRITISH JOURNAL OF DERMATOLOGY 108(4):467-471 LOVELL CR; HAWK JLM; CALNAN CD; MAGNUS IA THALIDOMIDE IN ACTINIC PRURIGO | 21 | 41 |
1362 | 0 | 0 | 163 1962 MEDICAL JOURNAL OF AUSTRALIA 2(7):273-& LOVELL R CONGENITAL ABNORMALITIES AND THALIDOMIDE | 0 | 0 |
1363 | 0 | 0 | 1627 2000 ARTHRITIS AND RHEUMATISM 43(9):S117-S117 Lowe D; Kredich DW; Schanberg LE Thalidomide: An effective and safe agent for the treatment of pediatric mixed connective tissue disease. | 0 | 0 |
1364 | 20 | 27 | 2647 2004 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 310(2):571-577 Lu J; Helsby N; Palmer BD; Tingle M; Baguley BC; Kestell P; Ching LM Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans | 0 | 0 |
1365 | 30 | 38 | 2434 2003 CLINICAL CANCER RESEARCH 9(5):1680-1688 Lu J; Palmer BD; Kestell P; Browett P; Baguley BC; Muller G; Ching LM Thalidomide metabolites in mice and patients with multiple myeloma | 5 | 6 |
1366 | 10 | 37 | 2549 2003 PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE 19(6):272-280 Lu KQ; Brenneman S; Burns R; Vink A; Gaines E; Haake A; Gaspari A Thalidomide inhibits UVB-induced mouse keratinocyte apoptosis by both TNF-alpha-dependent and TNF-alpha-independent pathways | 0 | 0 |
1367 | 3 | 7 | 262 1963 SCIENCE 139(356):1295-& LUCEY JF; BEHRMAN RE THALIDOMIDE - EFFECT UPON PROGNANCY IN RHESUS MONKEY | 17 | 37 |
1368 | 0 | 0 | 782 1982 EEG-EMG-ZEITSCHRIFT FUR ELEKTROENZEPHALOGRAPHIE ELEKTROMYOGRAPHIE UND VERWANDTE GEBIETE 13(4):167-170 LUDOLPH A; MATZ DR ELECTRONEUROGRAPHIC STUDIES IN PATIENTS UNDER THALIDOMIDE THERAPY OF LUPUS ERYTHEMATODES DISCOIDES | 6 | 1 |
1369 | 0 | 0 | 819 1983 ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY 56(3):S128-S128 LUDOLPH A; SCHULTE J; BRUNE GG ELECTRO-PHYSIOLOGICAL STUDIES CONCERNING THE REVERSIBILITY OF POLYNEUROPATHIES DUE TO THALIDOMIDE THERAPY OF LUPUS ERYTHEMATODES DISCOIDES | 0 | 0 |
1370 | 14 | 33 | 1002 1990 ACTA ENDOCRINOLOGICA 123(1):79-83 LUEPRASITSAKUL W; ABEND S; ALEX S; REINHARDT W; APPEL MC; BRAVERMAN LE EFFECT OF THALIDOMIDE ON THE INCIDENCE OF IODINE-INDUCED AND SPONTANEOUS LYMPHOCYTIC THYROIDITIS AND SPONTANEOUS DIABETES-MELLITUS IN THE BB/WOR RAT | 2 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1371 | 0 | 0 | 156 1962 LANCET 2(7269):1332-& LUERS H FAILURE OF MUTAGENIC ACTION OF THALIDOMIDE IN DROSOPHILA | 5 | 8 |
1372 | 0 | 0 | 161 1962 MEDICAL JOURNAL OF AUSTRALIA 1(24):949-& LUMER RH CONGENITAL ABNORMALITIES AND THALIDOMIDE | 1 | 1 |
1373 | 0 | 3 | 2423 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(4):748-748 Luminari S; Federico M; Baldini L Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide - Response to Mileshkin et al. | 0 | 0 |
1374 | 0 | 0 | 2083 2002 BLOOD 100(11):367B-367B Luo SK; Li J; Hong WD; Zhou ZH Immunoreactivity of thalidomide in patients with multiple myeloma. | 0 | 0 |
1375 | 0 | 3 | 441 1967 NATURE 214(5092):1018-& LUTWAKMA.C; SCHMID K; KEBERLE H THALIDOMIDE IN RABBIT SEMEN | 0 | 40 |
1376 | 0 | 2 | 275 1964 BRITISH MEDICAL JOURNAL 1(539):1090-& LUTWAKMANN C OBSERVATIONS ON PROGENY OF THALIDOMIDE-TREATED MALE RABBITS | 8 | 36 |
1377 | 0 | 1 | 276 1964 BRITISH MEDICAL JOURNAL 1(539):1559-& LUTWAKMANN C THALIDOMIDE-TREATED MALE RABBITS | 0 | 0 |
1378 | 42 | 78 | 2624 2004 EXPERT OPINION ON THERAPEUTIC PATENTS 14(2):215-229 Luzzio FA; Figg WD Thalidomide analogues: derivatives of an orphan drug with diverse biological activity | 0 | 0 |
1379 | 0 | 0 | 1800 2001 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 222:U685-U685 Luzzio FA; Figg WD; Mayorov AV; Kruger EA Thalidomide metabolites and analogs, part 3: Synthesis and antiangiogenic activity of the teratogenic and TNF-alpha-modulatory thalidomide analog EM-12. | 0 | 0 |
1380 | 0 | 0 | 1605 2000 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 219:U227-U227 Luzzio FA; Mayorov AV; Figg WD Thalidomide metabolites: Preparation of (+)-2-(N-phthalimido)- 4-hydroxyglutamic acid derivatives. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1381 | 4 | 18 | 1795 2000 TETRAHEDRON LETTERS 41(14):2275-2278 Luzzio FA; Mayorov AV; Figg WD Thalidomide metabolites. Part 1: Derivatives of (+)-2-(N-phthalimido)-gamma-hydroxyglutamic acid | 3 | 7 |
1382 | 11 | 25 | 2490 2003 JOURNAL OF MEDICINAL CHEMISTRY 46(18):3793-3799 Luzzio FA; Mayorov AV; Ng SSW; Kruger EA; Figg WD Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNF alpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine | 0 | 0 |
1383 | 0 | 0 | 2293 2003 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 225:U197-U197 Luzzio FA; Ng SSW; Gutschow M; Hauschildt S; Weiss M; Teubert U; Kruger E; Mayorov AV; Eger K; Figg WD Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogs. | 0 | 0 |
1384 | 0 | 0 | 1480 1999 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 218:U58-U58 Luzzio FA; Thomas EM; Figg WD Stereoselective synthesis of thalidomide analogs. | 0 | 0 |
1385 | 0 | 0 | 1606 2000 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 220:U96-U96 Luzzio FA; Thomas EM; Figg WD Thalidomide analogs and metabolites: Cyclic and acyclic derivatives of 2S, 3S-2-N-phthalimido(3-hydroxy)ornithine. | 0 | 0 |
1386 | 8 | 25 | 1796 2000 TETRAHEDRON LETTERS 41(37):7151-7155 Luzzio FA; Thomas EM; Figg WD Thalidomide metabolites and analogs. Part 2: Cyclic derivatives of 2-N-phthalimido-2S,3S (3-hydroxy) ornithine | 4 | 6 |
1387 | 6 | 11 | 988 1989 BIOCHEMICAL SOCIETY TRANSACTIONS 17(1):114-115 LYNE C; GOWER DB RADIAL THIN-LAYER CHROMATOGRAPHIC AUTORADIOGRAPHIC SCANS OF STEROID-METABOLISM IN THE PRESENCE OF THALIDOMIDE | 0 | 1 |
1388 | 8 | 10 | 1184 1995 CLINICAL BIOCHEMISTRY 28(4):467-470 LYON AW; DURAN G; RAISYS VA DETERMINATION OF THALIDOMIDE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - METHODOLOGICAL STRATEGY FOR CLINICAL-TRIALS | 6 | 7 |
1389 | 4 | 5 | 1327 1997 CLINICAL CHEMISTRY 43(6):1095-1096 Lyon AW; Raisys VA Handling of blood samples for determination of thalidomide - Respond | 0 | 0 |
1390 | 4 | 19 | 2309 2003 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 130(12):1109-1112 Macario-Barrel A; Balguerie X; Joly P Treatment of erosive oral lichen planus with thalidomide | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1391 | 0 | 0 | 827 1983 NEW SCIENTIST 99(1371):457-457 MACKENZIE D SECRET TESTS SAY THALIDOMIDE IS MUTAGENIC | 0 | 0 |
1392 | 1 | 6 | 175 1962 PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE 109(3):511-& MACKENZIE RD; MCGRATH WR ABSORPTION OF THALIDOMIDE IN RAT | 25 | 29 |
1393 | 52 | 86 | 2443 2003 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 46:S49-S57 Macpherson GR; Franks M; Tomoaia-Cotisel A; Ando Y; Price DK; Figg WD Current status of thalidomide and its role in the treatment of metastatic prostate cancer | 0 | 1 |
1394 | 0 | 0 | 1225 1996 AIDS 10:P102-P102 MacRedmond R; Keating S; Armstrong S; Ryan M; Mulcahy FM The use of oral thalidomide in the treatment of oesophageal ulceration in AIDS. | 0 | 0 |
1395 | 0 | 0 | 1540 1999 GASTROENTEROLOGY 116(4):A767-A767 Macumber C; Wettstein AP; Vickers CR; Hing M; Edwards PD; Byrnes DJ; Meagher AP Thalidomide-effective therapy in chronic resistant inflammatory bowel disease. Department of gastroenterology. St. Vincent's Hospital, Sydney, Australia. | 2 | 3 |
1396 | 0 | 0 | 30 1961 BRITISH MEDICAL JOURNAL 2(526):1359-& MAGRATH D NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 2 | 2 |
1397 | 0 | 0 | 1951 2001 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 42(4):S233-S233 Maguire MG; Fine SL; Maguire AM; D'Amato RJ; Singerman LJ Results of the age-related macular degeneration and thalidomide study (AMDATS). | 0 | 5 |
1398 | 22 | 67 | 167 1962 NEW ENGLAND JOURNAL OF MEDICINE 267(23):1179-& MAHON WA; MITCHELL ML; KATZENSTEIN M; STEINKE J; RABEN MS SAGA OF THALIDOMIDE - NEUROPATHY TO EMBRYOPATHY, WITH CASE REPORTS OF CONGENITAL ANOMALIES | 0 | 35 |
1399 | 3 | 13 | 312 1965 ARCHIVES OF DISEASE IN CHILDHOOD 40(210):154-& MAIER WA THALIDOMIDE EMBRYOPATHY AND LIMB DEFECTS - EXPERIENCES IN HABILITATION OF CHILDREN WITH ECTROMELIAS | 0 | 1 |
1400 | 2 | 3 | 392 1966 LANCET 1(7438):665-& MAINARDI PC; BORRONE C; TAMBUSSI AM ANOTHER CHANCE FOR THALIDOMIDE | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1401 | 4 | 26 | 1915 2001 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 126(42):1183-1186 Maio G On the history of the Contergan (thalidomide) catastrophe in the light of drug legislation | 0 | 3 |
1402 | 37 | 67 | 2230 2002 JOURNAL OF IMMUNOLOGY 168(6):2644-2651 Majumdar S; Lamothe B; Aggarwal BB Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester | 12 | 24 |
1403 | 1 | 24 | 1112 1993 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 90(13):5974-5978 MAKONKAWKEYOON S; LIMSONPOBRE RNR; MOREIRA AL; SCHAUF V; KAPLAN G THALIDOMIDE INHIBITS THE REPLICATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 | 105 | 184 |
1404 | 7 | 25 | 2564 2003 WORLD JOURNAL OF SURGERY 27(10):1119-1123 Mall JW; Schwenk W; Philipp AW; Buttemeyer R; Pollmann C Intraperitoneal administration of the angiogenesis inhibitor thalidomide does not impair anastomotic healing following large bowel resection in a rabbit model | 0 | 0 |
1405 | 8 | 23 | 2182 2002 EUROPEAN JOURNAL OF SURGERY 168(11):641-645 Mall JW; Schwenk W; Philipp AW; Muller JM; Pollmann C Thalidomide given intraperitoneally reduces the number of postoperative adhesions after large bowel resection in rabbits | 0 | 0 |
1406 | 0 | 0 | 2406 2003 BRITISH JOURNAL OF CANCER 88:S46-S46 Malpas J; Chaplin T; Sanmugathasan A; Liu W In vitro activity of S-thalidomide against multiple myeloma cells: A gene and protein expression profile. | 0 | 0 |
1407 | 13 | 26 | 2336 2003 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 13(20):3415-3417 Man HW; Corral LG; Stirling DI; Muller GW alpha-fluoro-substituted thalidomide analogues | 1 | 1 |
1408 | 4 | 18 | 1206 1995 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 33(2):380-382 MANDERS SM; KOSTMAN JR; MENDEZ L; RUSSIN VL THALIDOMIDE-RESISTANT HIV-ASSOCIATED APHTHAE SUCCESSFULLY TREATED WITH GRANULOCYTE-COLONY-STIMULATING FACTOR | 1 | 7 |
1409 | 0 | 0 | 631 1976 TERATOLOGY 13(2):A29-A29 MANSON JM; SMITH CC EFFECTS OF THALIDOMIDE, EM-8 AND EM12 ON INVITRO DEVELOPMENT OF EMBRYONIC MOUSE LIMBS | 0 | 0 |
1410 | 0 | 0 | 2076 2002 BLOOD 100(11):265B-265B Manson SD; Gregory SA; Rogers K; Raza A; Loew J; Hsu WT; Sivaraman S; Venugopal P Thalidomide as a single agent leads to meaningful responses in older patients with poor prognosis acute myeloid leukemia (PP-AML) | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1411 | 0 | 0 | 1848 2001 BLOOD 98(11):215B-215B Manson SD; Venugopal P; Gregory SA; Raza A; Sivaraman S; Preisler H Treatment of relapsed/refractory acute myeloid leukemia (AML) with thalidomide as a single agent: Clinical and biologic responses. | 0 | 0 |
1412 | 5 | 8 | 965 1988 BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY 95(7):717-719 MAOURIS PG; HIRSCH PJ PREGNANCY IN WOMEN WITH THALIDOMIDE-INDUCED DISABILITIES - CASE-REPORT AND A QUESTIONNAIRE STUDY | 0 | 4 |
1413 | 8 | 24 | 2635 2004 JOURNAL OF CLINICAL ONCOLOGY 22(3):424-431 Marchetti M; Barosi G; Balestri F; Viarengo G; Gentili S; Barulli S; Demory JL; Ilariucci F; Volpe A; Bordessoule D; Grossi A; Le Bousse-Kerdiles MC; Caenazzo A; Pecci A; Falcone A; Broccia G; Bendotti C; Bauduer F; Buccisano F; Dupriez B Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: A phase II trial | 0 | 0 |
1414 | 3 | 12 | 338 1965 JOURNAL OF EMBRYOLOGY AND EXPERIMENTAL MORPHOLOGY 13:235-& MARINPAD.M; BENIRSCH.K THALIDOMIDE INJURY TO MYOCARDIUM OF ARMADILLO EMBRYOS | 0 | 4 |
1415 | 2 | 7 | 270 1964 ANATOMICAL RECORD 149(3):359-& MARINPADILLA M THALIDOMIDE INJURY TO IMPLANTED ARMADILLO BLASTOCYST | 3 | 6 |
1416 | 4 | 25 | 187 1963 AMERICAN JOURNAL OF PATHOLOGY 43(6):999-& MARINPADILLA M; BENIRSCHKE K THALIDOMIDE INDUCED ALTERATIONS IN BLASTOCYST AND PLACENTA OF ARMADILLO, DASYPUS NOVEMCINCTUS MEXICANUS, INCLUDING A CHORIOCARCINOMA | 6 | 35 |
1417 | 1 | 26 | 2545 2003 PEDIATRIC NEUROLOGY 29(2):151-156 Marjanovic BD; Stojanov LM; Zdravkovic DS; Kravljanac RM; Djordjevic MS Rasmussen syndrome and long-term response to thalidomide | 0 | 0 |
1418 | 39 | 71 | 2041 2002 BIOLOGICAL & PHARMACEUTICAL BULLETIN 25(5):597-604 Marks MG; Shi JD; Fry MO; Xiao ZL; Trzyna M; Pokala V; Ihnat MA; Li PK Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation | 6 | 9 |
1419 | 0 | 0 | 2133 2002 BRITISH JOURNAL OF CANCER 86:S117-S118 Marriott JB; Clarke IA; Czajka A; Dredge K; Childs K; Man HW; Schafer P; Govinda S; Muller GW; Stirling D; Dalgleish AG A novel subclass of thalidomide analogue with anti-solid tumour activity in which caspase dependent apoptosis is associated with altered expression of BCL-2 family proteins | 0 | 0 |
1420 | 22 | 28 | 2428 2003 CANCER RESEARCH 63(3):593-599 Marriott JB; Clarke IA; Czajka A; Dredge K; Childs K; Man HW; Schafer P; Govinda S; Muller GW; Stirling DI; Dalgleish AG A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins | 6 | 13 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1421 | 33 | 37 | 2157 2002 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 130(1):75-84 Marriott JB; Clarke IA; Dredge K; Muller G; Stirling D; Dalgleish AG Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells | 15 | 17 |
1422 | 0 | 0 | 2131 2002 BRITISH JOURNAL OF CANCER 86:S26-S26 Marriott JB; Clarke IA; Dredge K; Pandha H; Kristaleit H; Polychronis A; Muller GW; Stirling D; Dalgleish AG Thalidomide analogue CDC-501 is safe and well tolerated by patients with end stage cancer and shows evidence of clinical responses and extensive immune activation | 3 | 3 |
1423 | 7 | 20 | 1305 1997 AIDS RESEARCH AND HUMAN RETROVIRUSES 13(18):1625-1631 Marriott JB; Cookson S; Carlin E; Youle M; Hawkins DA; Nelson M; Pearson P; Vaughan AN; Gazzard B; Dalgleish AG A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: Clinical tolerance and effect on activation markers and cytokines | 9 | 14 |
1424 | 0 | 0 | 1265 1996 IMMUNOLOGY 89:ORI27-ORI27 Marriott JB; Cookson S; Westby M; Guckian M; Dalgleish AG The effect of a thalidomide analogue on TNF-alpha/cytokine production in vitro | 0 | 0 |
1425 | 43 | 52 | 1549 1999 IMMUNOLOGY TODAY 20(12):538-540 Marriott JB; Muller G; Dalgleish AG Thalidomide as an emerging immunotherapeutic agent | 36 | 45 |
1426 | 44 | 53 | 1925 2001 EXPERT OPINION ON BIOLOGICAL THERAPY 1(4):675-682 Marriott JB; Muller G; Stirling D; Dalgleish AG Immunotherapeutic and antitumour potential of thalidomide analogues | 11 | 15 |
1427 | 14 | 30 | 1445 1998 JOURNAL OF IMMUNOLOGY 161(8):4236-4243 Marriott JB; Westby M; Cookson S; Guckian M; Goodbourn S; Muller G; Shire MG; Stirling D; Dalgleish AG CC-3052: A water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production | 33 | 49 |
1428 | 9 | 12 | 264 1964 AMERICAN HEART JOURNAL 67(2):184-& MARTIN JK CONGENITAL MALFORMATIONS ASSOCIATED WITH THALIDOMIDE + THEIR MANAGEMENT | 0 | 0 |
1429 | 7 | 9 | 204 1963 CANADIAN MEDICAL ASSOCIATION JOURNAL 88(19):959-& MARTIN JK; RATHBUN JC HABILITATION OF PATIENTS WITH CONGENITAL MALFORMATIONS ASSOCIATED WITH THALIDOMIDE - PEDIATRIC ASPECTS | 4 | 4 |
1430 | 1 | 7 | 9 1960 JOURNAL OF PHARMACY AND PHARMACOLOGY 12:T153-T158 MARTINDALE K; SOMERS GF; WILSON CWM THE EFFECT OF THALIDOMIDE IN EXPERIMENTAL GASTRIC ULCERS | 0 | 15 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1431 | 0 | 0 | 1618 2000 ANNALS OF ONCOLOGY 11:54-54 Martinelli G; Mingrone W; Alietti A; Ferrucci F; Cocorocchio E; Peccatori F; Cinieri S; Corsini C; Zucca E; Bertolini F Clinical efficacy of thalidomide in multiple myeloma (MM), myelodysplastic syndromes (MDS) and histiocytosis | 0 | 0 |
1432 | 0 | 0 | 1558 1999 JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 103(1):S20-S20 Martinez A; Hernandez T; Hernandez V; Espinosa F Thalidomide for pertinacious vasculitic syndrome secondary to coxsackie A virus infection. | 0 | 0 |
1433 | 0 | 0 | 1438 1998 HEPATOLOGY 28(4):460A-460A Martinez L; Lopez-Talavera JC; Martinez M; Cadelina G; Pachon JC; Esteban R; Guardia J; Groszmann RJ Amelioration of the hyperdynamic syndrome of cirrhotic rats by thalidomide. | 0 | 0 |
1434 | 0 | 0 | 1351 1997 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 278(14):1135-1137 Marwick C Thalidomide back - Under strict control | 10 | 13 |
1435 | 7 | 29 | 1967 2001 JOURNAL OF NEURO-ONCOLOGY 54(1):31-38 Marx GM; Pavlakis N; McCowatt S; Boyle FM; Levi JA; Bell DR; Cook R; Biggs M; Little N; Wheeler HR Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme | 13 | 20 |
1436 | 0 | 0 | 690 1979 ARCHIVES OF DERMATOLOGY 115(5):636-637 MASCARO JM; LECHA M; TORRAS H THALIDOMIDE IN THE TREATMENT OF RECURRENT, NECROTIC, AND GIANT MUCOCUTANEOUS APHTHAE AND APHTHOSIS | 64 | 78 |
1437 | 12 | 26 | 2042 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):1-3 Mathe G Thalidomide, a drug which may protect the organism against some aggressive effects of the immunologic system | 0 | 0 |
1438 | 1 | 8 | 884 1985 EXPERIMENTAL ANIMALS 34(3):295-302 MATSUBARA Y; MIKAMI T TERATOGENIC POTENTIALITY OF SINGLE DOSE OF THALIDOMIDE IN JW-NIBS RABBITS | 0 | 1 |
1439 | 0 | 0 | 869 1984 TERATOLOGY 30(1):A36-A36 MATSUMOTO Y; HAMADA Y FINDINGS OF THE UROGENITAL ORGAN SYSTEMS OF THALIDOMIDE EMBRYOPATHY | 0 | 0 |
1440 | 166 | 221 | 2442 2003 CLINICAL THERAPEUTICS 25(2):342-395 Matthews SJ; McCoy C Thalidomide: A review of approved and investigational uses | 2 | 5 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1441 | 0 | 0 | 688 1978 ZEITSCHRIFT FUR ORTHOPADIE UND IHRE GRENZGEBIETE 116(4):571-572 MATTHIASS HH; RUFFING L DEVELOPMENT OF SKELETAL AND MOTOR APPARATUS IN ADOLESCENTS WITH THALIDOMIDE EMBRYOPATHY | 0 | 0 |
1442 | 0 | 4 | 388 1966 JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 195(8):695-& MATTHIES F TRIAD OF ANOTIA FACIAL PARALYSIS AND CARDIAC ANOMALY NOT DUE TO THALIDOMIDE | 0 | 3 |
1443 | 30 | 47 | 2581 2004 ARCHIVES OF DERMATOLOGY 140(7):845-849 Maurer T; Poncelet A; Berger T Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects - Efficacy and risk of neuropathy | 0 | 0 |
1444 | 8 | 15 | 916 1986 BRITISH JOURNAL OF DERMATOLOGY 115(6):677-680 MAURICE PDL; BARKLEY ASJ; ALLEN BR THE EFFECT OF THALIDOMIDE ON ARACHIDONIC-ACID METABOLISM IN HUMAN POLYMORPHONUCLEAR LEUKOCYTES AND PLATELETS | 5 | 5 |
1445 | 5 | 29 | 1968 2001 JOURNAL OF NEURO-ONCOLOGY 55(1):11-17 Mawrin C; Aumann V; Kirches E; Schneider-Stock R; Scherlach C; Vogel S; Mittler U; Dietzmann K; Krause G; Weis S Gliomatosis cerebri: Post-mortem molecular and immunohistochemical analyses in a case treated with thalidomide | 0 | 4 |
1446 | 4 | 6 | 2265 2002 MEDICAL JOURNAL OF AUSTRALIA 177(5):278-278 McBride W Thalidomide and cancer | 1 | 1 |
1447 | 3 | 5 | 2653 2004 LANCET 363(9403):169-169 McBride W Health of thalidomide victims and their progeny | 0 | 0 |
1448 | 0 | 0 | 45 1961 LANCET 2(721):1358-& MCBRIDE WG THALIDOMIDE AND CONGENITAL ABNORMALITIES | 181 | 432 |
1449 | 0 | 0 | 48 1961 MEDICAL JOURNAL OF AUSTRALIA 2(26):1030-& MCBRIDE WG CONGENITAL ABNORMALITIES AND THALIDOMIDE | 3 | 4 |
1450 | 0 | 0 | 341 1965 LANCET 2(7417):855-& MCBRIDE WG THALIDOMIDE | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1451 | 0 | 0 | 603 1974 TERATOLOGY 9(3):A27-A28 MCBRIDE WG HISTOLOGICAL STUDY OF NEURONS OF DORSAL ROOT GANGLIA IN OFFSPRING OF PREGNANT RABBITS TREATED WITH THALIDOMIDE AND OTHER AGENTS | 0 | 0 |
1452 | 2 | 13 | 604 1974 TERATOLOGY 10(3):283-291 MCBRIDE WG FETAL NERVE-CELL DEGENERATION PRODUCED BY THALIDOMIDE IN RABBITS | 11 | 28 |
1453 | 0 | 0 | 605 1974 TERATOLOGY 10(3):317-317 MCBRIDE WG HISTOLOGICAL STUDY OF NEURONS OF DORSAL ROOT GANGLIA IN OFFSPRING OF PREGNANT RABBITS TREATED WITH THALIDOMIDE AND OTHER AGENTS | 0 | 0 |
1454 | 6 | 20 | 633 1976 TERATOLOGY 14(1):71-87 MCBRIDE WG STUDIES OF ETIOLOGY OF THALIDOMIDE DYSMORPHOGENESIS | 6 | 28 |
1455 | 14 | 24 | 658 1977 TERATOLOGY 16(1):79-82 MCBRIDE WG THALIDOMIDE EMBRYOPATHY | 11 | 29 |
1456 | 3 | 7 | 676 1978 LANCET 1(8078):1362-1362 MCBRIDE WG TERATOGENIC ACTION OF THALIDOMIDE | 1 | 1 |
1457 | 0 | 0 | 757 1981 LANCET 2(8242):368-368 MCBRIDE WG ANOTHER, LATE THALIDOMIDE ABNORMALITY | 1 | 1 |
1458 | 3 | 4 | 1128 1994 BRITISH MEDICAL JOURNAL 308(6944):1635-1636 MCBRIDE WG THALIDOMIDE MAY BE A MUTAGEN | 16 | 22 |
1459 | 0 | 0 | 978 1988 TERATOLOGY 38(2):199-199 MCBRIDE WG; CATALANO A; DUGUID P; HICKS L THE EFFECT OF THALIDOMIDE ADMINISTRATION ON GABA AND OTHER AMINO-ACIDS IN THE MARMOSET EMBRYO | 0 | 0 |
1460 | 5 | 10 | 781 1982 DEVELOPMENT GROWTH & DIFFERENTIATION 24(2):217-222 MCBRIDE WG; STOKES PA; VARDY PH MATERNAL THALIDOMIDE TREATMENT AND CELL-DIVISION IN CULTURED RABBIT EMBRYOS - AUTOMATED IMAGE-ANALYSIS OF AUTORADIOGRAPHS | 2 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1461 | 0 | 0 | 791 1982 TERATOLOGY 25(2):A61-A61 MCBRIDE WG; VARDY P; STOKES PA THE MECHANISM OF THALIDOMIDE TERATOGENISM IN THE RABBIT LIMB | 0 | 0 |
1462 | 13 | 34 | 818 1983 DEVELOPMENT GROWTH & DIFFERENTIATION 25(4):361-373 MCBRIDE WG; VARDY PH PATHOGENESIS OF THALIDOMIDE TERATOGENESIS IN THE MARMOSET (CALLITHRIX-JACCHUS) - EVIDENCE SUGGESTING A POSSIBLE TROPHIC INFLUENCE OF CHOLINERGIC NERVES IN LIMB MORPHOGENESIS | 1 | 6 |
1463 | 15 | 52 | 309 1965 AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 91(2):260-& MCCAFFER.RE; WOOD ML; KNISELY WH MORPHOLOGICAL AND PHYSIOLOGICAL EFFECTS OF THALIDOMIDE AND TRYPAN BLUE ON UTERI AND CONCEPTI OF GRAVID MICE | 0 | 2 |
1464 | 2 | 2 | 974 1988 LANCET 2(8620):1135-1135 MCCARTHY DM; KANFER E; TAYLOR J; BARRETT AJ THALIDOMIDE FOR GRAFT-VERSUS-HOST DISEASE | 19 | 21 |
1465 | 15 | 23 | 989 1989 BIOMEDICINE & PHARMACOTHERAPY 43(9):693-697 MCCARTHY DM; KANFER EJ; BARRETT AJ THALIDOMIDE FOR THE THERAPY OF GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION | 15 | 17 |
1466 | 23 | 108 | 1370 1997 MEDICAL HYPOTHESES 49(2):123-131 McCarty MF Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: Potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis | 17 | 31 |
1467 | 10 | 22 | 323 1965 CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY 43(1):69-& MCCOLL JD; GLOBUS M; ROBINSON S AN ATTEMPTED REVERSAL OF THALIDOMIDE EMBRYOPATHY IN RAT BY GLUTAMINE | 7 | 10 |
1468 | 10 | 25 | 1146 1994 JOURNAL OF HEPATOLOGY 21(4):496-499 MCCORMICK PA; SCOTT F; EPSTEIN O; BURROUGHS AK; SCHEUER PJ; MCINTYRE N THALIDOMIDE AS THERAPY FOR PRIMARY BILIARY-CIRRHOSIS - A DOUBLE-BLIND PLACEBO-CONTROLLED PILOT-STUDY | 6 | 11 |
1469 | 3 | 12 | 576 1973 LANCET 2(7837):1058-1061 MCCREDIE J THALIDOMIDE AND CONGENITAL CHARCOTS JOINTS | 8 | 49 |
1470 | 0 | 0 | 681 1978 TERATOLOGY 17(2):A42-A42 MCCREDIE J MECHANISM OF TERATOGENICITY COMMON TO THALIDOMIDE EMBRYOPATHY AND OTHER DYSMELIC SYNDROMES | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1471 | 0 | 0 | 766 1981 TERATOLOGY 23(2):A51-A51 MCCREDIE J THALIDOMIDE AND THE NEURAL CREST | 0 | 0 |
1472 | 1 | 2 | 1030 1990 TERATOLOGY 41(2):239-239 MCCREDIE J PROPOSED MECHANISMS OF ACTION IN THALIDOMIDE EMBRYOPATHY - COMMENT | 1 | 1 |
1473 | 1 | 3 | 598 1974 LANCET 1(7866):1111-1111 MCCREDIE J; MCLEOD JG THALIDOMIDE AND EMBRYONIC NEUROPATHY | 5 | 11 |
1474 | 11 | 42 | 854 1984 JOURNAL OF ANATOMY 139(OCT):397-410 MCCREDIE J; NORTH K; DEIONGH R THALIDOMIDE DEFORMITIES AND THEIR NERVE SUPPLY | 3 | 6 |
1475 | 12 | 52 | 1559 1999 JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME 81B(1):9-23 McCredie J; Willert HG Longitudinal limb deficiencies and the sclerotomes - An analysis of 378 dysmelic malformations induced by thalidomide | 0 | 7 |
1476 | 0 | 5 | 954 1988 ANAESTHESIA 43(7):613-614 MCCRORY JW ANESTHESIA AND THALIDOMIDE-RELATED ABNORMALITIES | 1 | 1 |
1477 | 0 | 9 | 566 1973 DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY 15(6):719-727 MCFIE J; ROBERTSO.J PSYCHOLOGICAL TEST RESULTS OF CHILDREN WITH THALIDOMIDE DEFORMITIES | 1 | 8 |
1478 | 15 | 34 | 1183 1995 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 99(2):160-167 MCHUGH SM; RIFKIN IR; DEIGHTON J; WILSON AB; LACHMANN PJ; LOCKWOOD CM; EWAN PW THE IMMUNOSUPPRESSIVE DRUG THALIDOMIDE INDUCES T-HELPER CELL-TYPE 2 (TH2) AND CONCOMITANTLY INHIBITS TH1 CYTOKINE PRODUCTION IN MITOGEN-STIMULATED AND ANTIGEN-STIMULATED HUMAN PERIPHERAL-BLOOD MONONUCLEAR CELL-CULTURES | 106 | 143 |
1479 | 31 | 50 | 1325 1997 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 110(2):151-154 McHugh SM; Rowland TL Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation | 17 | 32 |
1480 | 0 | 0 | 1337 1997 FORTUNE 136(6):36-& McLean B Thalidomide .2. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1481 | 0 | 1 | 489 1969 TERATOLOGY 2(3):265-& MCNULTY WP; WUEST HM THALIDOMIDE, TERATOGENY, AND STRUCTURE - TERATOGENIC ACTION OF WU 385 ON RHESUS | 0 | 0 |
1482 | 0 | 0 | 596 1974 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 229(13):1724-1724 MCWHIRTE.WW THALIDOMIDE REVISITED | 0 | 0 |
1483 | 0 | 0 | 27 1961 BRITISH MEDICAL JOURNAL 2(526):1223-& MEADE BW; ROSALKI SB NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 4 | 8 |
1484 | 4 | 12 | 2433 2003 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 21(2):272-272 Meaux-Ruault N; Magy N; Gil H; Dupond JL Efficacy of thalidomide in refractory adult Still's disease: A new case report | 0 | 0 |
1485 | 0 | 21 | 2028 2002 ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY 88(4):421-424 Medeiros M; Araujo MI; Guimaraes NS; Freitas LAR; Silva TMC; Carvalho EM Therapeutic response to thalidomide in Melkersson-Rosenthal syndrome: a case report | 1 | 2 |
1486 | 0 | 0 | 1316 1997 BLOOD 90(10):4423-4423 Mehta P; Gian VG; Smith SP; Beltz SE; Wingard JR Thalidomide is not effective for acute graft-versus-host disease. | 0 | 0 |
1487 | 3 | 6 | 2521 2003 LEUKEMIA 17(11):2237-2238 Mehta P; Hussein M Thalidomide as anti-inflammatory therapy for multiple myeloma | 0 | 0 |
1488 | 11 | 13 | 1594 1999 PEDIATRICS 103(4):art. no.-e44 Mehta P; Kedar A; Graham-Pole J; Skoda-Smith S; Wingard JR Thalidomide in children undergoing bone marrow transplantation: Series at a single institution and review of the literature | 0 | 10 |
1489 | 6 | 15 | 1565 1999 JOURNAL OF INFECTIOUS DISEASES 180(1):216-219 Meierhofer C; Dunzendorfer S; Wiederman CJ Protein kinase C-dependent effects on leukocyte migration of thalidomide | 5 | 10 |
1490 | 115 | 191 | 1823 2001 BIODRUGS 15(10):681-703 Meierhofer C; Dunzendorfer S; Wiedermann CJ Theoretical basis for the activity of thalidomide | 6 | 12 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1491 | 44 | 59 | 2445 2003 CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT 6(1):92-99 Meierhofer C; Wiedermann CJ New insights into the pharmacological and toxicological effects of thalidomide | 3 | 3 |
1492 | 6 | 10 | 557 1972 PHARMAZIE 27(6):418-& MEISE W SYNTHESIS AND TERATOLOGICAL TESTING OF SOME THALIDOMIDE METABOLITES | 2 | 4 |
1493 | 8 | 17 | 568 1973 EXPERIENTIA 29(4):423-424 MEISE W; OCKENFEL.H; KOHLER F TERATOLOGICAL TESTING OF HYDROLYTIC PRODUCTS OF THALIDOMIDE | 9 | 15 |
1494 | 0 | 168 1962 NEW ENGLAND JOURNAL OF MEDICINE 267(23):1184-1192 MELLIN GW; KATZENSTEIN M THE SAGA OF THALIDOMIDE. NEUROPATHY TO EMBRYOPATHY, WITH CASE REPORTS OF CONGENITAL ANOMALIES | 83 | 169 | |
1495 | 34 | 65 | 169 1962 NEW ENGLAND JOURNAL OF MEDICINE 267(24):1238-1244 MELLIN GW; KATZENSTEIN M THE SAGA OF THALIDOMIDE. NEUROPATHY TO EMBRYOPATHY, WITH CASE REPORTS OF CONGENITAL ANOMALIES | 64 | 109 |
1496 | 1 | 5 | 201 1963 CANADIAN JOURNAL OF CHEMISTRY-REVUE CANADIENNE DE CHIMIE 41(7):1722-& MENARD M; ERICHOMO.L; LABROOY M; CHUBB FL QUELQUES METABOLITES POSSIBLES DE LA THALIDOMIDE | 3 | 8 |
1497 | 3 | 23 | 2612 2004 CLINICAL NEPHROLOGY 61(5):352-356 Menegato MA; Canelles MF; Tonutti E; Pizzolitto S Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease | 0 | 0 |
1498 | 0 | 0 | 2094 2002 BLOOD 100(11):387B-387B Meng HT; Jin J; Mai WY Thalidomide plus M2 chemotherapy in the treatment of refractory multiple myeloma. | 0 | 0 |
1499 | 0 | 0 | 1108 1993 PEDIATRIC DERMATOLOGY 10(3):283-285 MENNI S; IMONDI D; BRANCALEONE W; CROCI S RECURRENT GIANT APHTHOUS ULCERS IN A CHILD - PROTRACTED TREATMENT WITH THALIDOMIDE | 5 | 10 |
1500 | 6 | 6 | 2172 2002 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 127(15):818-818 Mensing H New indication for thalidomide? | 0 | 0 |
Page 5: 1 2 3 4 5 6 7 8 9
Generated by:
HistCite(Vlad).
Version: 2004.09.22